… will focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic … exclusively on accelerating the development of its Axiomer RNA-editing platform technology. Initial therapeutic areas …
This month several ProQRians will attend the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 to highlight our Axiomer RNA-editing platform technology.
… on developing potential medicines using our Axiomer™ RNA editing platform technology. Strategic collaborations … greater understanding, we can drive higher standards of RNA-editing, medicinal application, and effectiveness of our …
… event, the Company will showcase its proprietary Axiomer ® RNA-editing technology platform, announce initial pipeline … for the ADAR enzymes responsible for adenosine to inosine RNA editing in humans. In addition, his group has led in the … a virtual R&D event to showcase its proprietary Axiomer RNA-editing technology platform. ProQR will also announce …
… on developing potential medicines using our Axiomer RNA editing platform technology. Strategic collaborations … exclusively on furthering the development of our Axiomer RNA editing platform technology , which allows selective … in September 2021 , applied ProQR’s proprietary Axiomer™ RNA editing platform to target disorders of the liver and …
